Matches in SemOpenAlex for { <https://semopenalex.org/work/W2724252873> ?p ?o ?g. }
- W2724252873 endingPage "73500" @default.
- W2724252873 startingPage "73483" @default.
- W2724252873 abstract "// Peter Valent 1,2 , Attilio Orazi 3 , David P. Steensma 4 , Benjamin L. Ebert 5 , Detlef Haase 6 , Luca Malcovati 7 , Arjan A. van de Loosdrecht 8 , Torsten Haferlach 9 , Theresia M. Westers 8 , Denise A. Wells 10 , Aristoteles Giagounidis 11 , Michael Loken 10 , Alberto Orfao 12 , Michael Lübbert 13 , Arnold Ganser 14 , Wolf-Karsten Hofmann 15 , Kiyoyuki Ogata 16 , Julie Schanz 6 , Marie C. Béné 17 , Gregor Hoermann 18 , Wolfgang R. Sperr 1,2 , Karl Sotlar 19 , Peter Bettelheim 20 , Reinhard Stauder 21 , Michael Pfeilstöcker 22 , Hans-Peter Horny 23 , Ulrich Germing 24 , Peter Greenberg 25 and John M. Bennett 26 1 Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria 2 Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria 3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA 4 Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 5 Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 6 Clinic of Hematology and Medical Oncology, Universitymedicine Göttingen, Göttingen, Germany 7 Department of Molecular Medicine, University of Pavia, Pavia, Italy 8 Department of Hematology Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands 9 Munich Leukemia Laboratory (MLL), Munich, Germany 10 Hematologics, Inc., Seattle, WA, USA 11 Department of Internal Medicine II, Marien Hospital, Düsseldorf, Germany 12 Servicio Central de Citometría, Centro de Investigación del Cáncer (IBMCC, CSIC-USAL) and IBSAL, Universidad de Salamanca, Salamanca, Spain 13 Department of Medicine I, Medical Center-University of Freiburg, Freiburg, Germany 14 Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany 15 Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany 16 Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan), Tokyo, Japan 17 Laboratoire d’Hématologie CHU de Nantes, Nantes, France 18 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria 19 Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria 20 Elisabethinen Hospital, Linz, Austria 21 Department of Internal Medicine V (Haematology and Oncology) Innsbruck Medical University, Innsbruck, Austria 22 3rd Medical Department, Hanusch Hospital, Vienna, Austria 23 Institute of Pathology, Ludwig-Maximilians University, Munich, Germany 24 Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany 25 Stanford University Cancer Institute, Stanford, CA, USA 26 Department of Pathology, Hematopathology Unit and James P Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA Correspondence to: Peter Valent, email: // Keywords : myelodysplasia, diagnostic criteria, standardization, pre-MDS conditions Received : May 03, 2017 Accepted : June 26, 2017 Published : July 05, 2017 Abstract Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice." @default.
- W2724252873 created "2017-07-14" @default.
- W2724252873 creator A5005172825 @default.
- W2724252873 creator A5006306448 @default.
- W2724252873 creator A5011302710 @default.
- W2724252873 creator A5012626021 @default.
- W2724252873 creator A5013231760 @default.
- W2724252873 creator A5013460374 @default.
- W2724252873 creator A5025663121 @default.
- W2724252873 creator A5026124941 @default.
- W2724252873 creator A5031160909 @default.
- W2724252873 creator A5037453366 @default.
- W2724252873 creator A5041683169 @default.
- W2724252873 creator A5043227502 @default.
- W2724252873 creator A5043414993 @default.
- W2724252873 creator A5043678326 @default.
- W2724252873 creator A5047616627 @default.
- W2724252873 creator A5047951694 @default.
- W2724252873 creator A5052655746 @default.
- W2724252873 creator A5053537794 @default.
- W2724252873 creator A5056569874 @default.
- W2724252873 creator A5063746286 @default.
- W2724252873 creator A5065804627 @default.
- W2724252873 creator A5068303471 @default.
- W2724252873 creator A5070668676 @default.
- W2724252873 creator A5072513476 @default.
- W2724252873 creator A5072949561 @default.
- W2724252873 creator A5080057087 @default.
- W2724252873 creator A5084550885 @default.
- W2724252873 creator A5088409474 @default.
- W2724252873 creator A5090527595 @default.
- W2724252873 date "2017-07-05" @default.
- W2724252873 modified "2023-10-14" @default.
- W2724252873 title "Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions" @default.
- W2724252873 cites W1539455863 @default.
- W2724252873 cites W1744614805 @default.
- W2724252873 cites W1830664019 @default.
- W2724252873 cites W1865922929 @default.
- W2724252873 cites W1867592124 @default.
- W2724252873 cites W187238933 @default.
- W2724252873 cites W1972402895 @default.
- W2724252873 cites W1975350316 @default.
- W2724252873 cites W1985823023 @default.
- W2724252873 cites W1987311483 @default.
- W2724252873 cites W1987888032 @default.
- W2724252873 cites W1988241631 @default.
- W2724252873 cites W1993236149 @default.
- W2724252873 cites W1994148156 @default.
- W2724252873 cites W1997757445 @default.
- W2724252873 cites W1998367819 @default.
- W2724252873 cites W2006178295 @default.
- W2724252873 cites W2008625765 @default.
- W2724252873 cites W2009854509 @default.
- W2724252873 cites W2013169247 @default.
- W2724252873 cites W2023560061 @default.
- W2724252873 cites W2026134786 @default.
- W2724252873 cites W2027762423 @default.
- W2724252873 cites W2033666853 @default.
- W2724252873 cites W2034646423 @default.
- W2724252873 cites W2035471998 @default.
- W2724252873 cites W2036453074 @default.
- W2724252873 cites W2039199071 @default.
- W2724252873 cites W2041445112 @default.
- W2724252873 cites W2046562108 @default.
- W2724252873 cites W2048459239 @default.
- W2724252873 cites W2052176049 @default.
- W2724252873 cites W2055129321 @default.
- W2724252873 cites W2055445052 @default.
- W2724252873 cites W2058555053 @default.
- W2724252873 cites W2058643615 @default.
- W2724252873 cites W2061862949 @default.
- W2724252873 cites W2062965190 @default.
- W2724252873 cites W2064505089 @default.
- W2724252873 cites W2064548379 @default.
- W2724252873 cites W2069175777 @default.
- W2724252873 cites W2070152906 @default.
- W2724252873 cites W2070518872 @default.
- W2724252873 cites W2070831760 @default.
- W2724252873 cites W2071274943 @default.
- W2724252873 cites W2071599110 @default.
- W2724252873 cites W2076367236 @default.
- W2724252873 cites W2082339442 @default.
- W2724252873 cites W2083966256 @default.
- W2724252873 cites W2086209337 @default.
- W2724252873 cites W2086756578 @default.
- W2724252873 cites W2092772815 @default.
- W2724252873 cites W2097964210 @default.
- W2724252873 cites W2098258699 @default.
- W2724252873 cites W2100191214 @default.
- W2724252873 cites W2107398329 @default.
- W2724252873 cites W2115211756 @default.
- W2724252873 cites W2116325227 @default.
- W2724252873 cites W2119478585 @default.
- W2724252873 cites W2120972573 @default.
- W2724252873 cites W2126816979 @default.
- W2724252873 cites W2126956361 @default.
- W2724252873 cites W2129430680 @default.
- W2724252873 cites W2139410495 @default.